{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T23:39:55Z","timestamp":1792366795865,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":91,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1DA049406"],"award-info":[{"award-number":["UM1DA049406"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Medications for opioid use disorder (MOUD) have been proven to be the most effective method for treating individuals with opioid use disorder (OUD). Individuals who are retained on methadone and buprenorphine treatment have a decreased risk of mortality when compared to others with OUD. However, many individuals in need of MOUD face transportation barriers that prevent them from having the requisite access to treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      As part of the evidence-based practices (EBPs) implemented throughout the HEALing (Helping to End Addiction Long-term\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) Communities Study (HCS), strategies to reduce transportation barriers to receiving methadone and buprenorphine at partner organizations were identified and implemented. Multiple strategies were employed including transportation agency contracts, bus passes, rideshare services, leased agency vans, and fuel cards. This study provides a description of the number of unique riders, including demographic and geographic characteristics, and the costs of providing these transportation services across participating counties.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Throughout 2023, we partnered with thirty agencies across eight counties to administer $437,481.69 in transportation support services to 7,923 individuals. These services were distributed primarily to individuals who were white (81.8%; 6,483), female (51.9%; 4,112) and between the ages of 35\u201354 (59.8%; 4,737). The number of individuals reached and expenses were largest among the five urban counties (5,999; $318,317.15), which averaged $53.06 per person. Within the five urban counties, we worked with 23 agency partners and the average agency costs were $10,993.72. Across the three rural counties, costs averaged $61.94 per person reached (1,924; $119,164.54). Among the seven agency partners across the three rural counties, average agency costs were $9,235.38.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>By gaining an understanding of the populations benefiting from these services, breadth of services provided, and the costs required to address this barrier to care, we may more effectively inform decision-makers on the resources needed to link and retain individuals in treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.gov, NCT04111939. Registered 30 September 2019,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04111939\" ext-link-type=\"uri\">https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04111939<\/jats:ext-link>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-026-00702-1","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:44:26Z","timestamp":1784569466000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analysis of the costs and reach of transportation services to reduce barriers to opioid use disorder (OUD) treatment: evidence from the Kentucky HEALing Communities Study"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5314-3262","authenticated-orcid":false,"given":"Drew D.","family":"Speer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua L.","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don Lochana","family":"Ekanayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Nakayima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Goetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Miles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Larimore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah K.","family":"Knudsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon L.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn E.","family":"McCollister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"#cr-split#-702_CR1.1","unstructured":"U.S. Overdose Deaths Decrease in 2023, First Time Since 2018 [Internet]"},{"key":"#cr-split#-702_CR1.2","unstructured":"2024 [cited 2024 May 21]. Available from: https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2024\/20240515.htm."},{"key":"702_CR2","unstructured":"Haffajee R, Sherry T, Dubenitz J, White J, Schwartz D, Stoller B, et al. U.S. Department of Health and Human Services Overdose Prevention Strategy [Internet]. Washington (DC): Office of the assistant secretary for planning and evaluation, U.S. Department of Health and Human Service; 2021. Available from: https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/101936da95b69acb8446a4bad9179cc0\/overdose-prevention-strategy.pdf."},{"issue":"2","key":"702_CR3","doi-asserted-by":"publisher","first-page":"e1920622","DOI":"10.1001\/jamanetworkopen.2019.20622","volume":"3","author":"SE Wakeman","year":"2020","unstructured":"Wakeman SE, Larochelle MR, Ameli O, Chaisson CE, McPheeters JT, Crown WH, et al. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. JAMA Netw Open. 2020;3(2):e1920622. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.20622.","journal-title":"JAMA Netw Open"},{"key":"702_CR4","unstructured":"Treatment Options for Substance Use Disorder [Internet]; 2025 [cited 2026 Apr 28]. Available from: https:\/\/www.samhsa.gov\/substance-use\/treatment\/options."},{"issue":"5","key":"702_CR5","doi-asserted-by":"publisher","first-page":"759","DOI":"10.15288\/jsad.24-00150","volume":"85","author":"DH Gustafson","year":"2024","unstructured":"Gustafson DH, Molfenter T, Kunes T, Langdon L, Koplin M, Parker F, et al. Delivering MOUD to the Underserved: How Can Pharmacies Really Help? J Stud Alcohol Drugs. 2024;85(5):759\u201364. https:\/\/doi.org\/10.15288\/jsad.24-00150. PubMed PMID: 38995639; PubMed Central PMCID: PMC11533931.","journal-title":"J Stud Alcohol Drugs"},{"issue":"8","key":"702_CR6","doi-asserted-by":"publisher","first-page":"e2527418","DOI":"10.1001\/jamanetworkopen.2025.27418","volume":"8","author":"LE Hendy","year":"2025","unstructured":"Hendy LE, Hill LG, Olguin A, Barrett E, Jimes C, Coffey MJ, et al. Pharmacy Barriers to Receiving Buprenorphine Among Patients Undergoing Telemedicine Addiction Treatment. JAMA Netw Open. 2025;8(8):e2527418. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.27418.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"702_CR7","doi-asserted-by":"publisher","first-page":"e250001","DOI":"10.1001\/jamanetworkopen.2025.0001","volume":"8","author":"EE McGinty","year":"2025","unstructured":"McGinty EE, Ge Y, Yu J, Tormohlen KN, Eisenberg MD. Tele-Buprenorphine Initiations for Opioid Use Disorder Without In-Person Relationships. JAMA Netw Open. 2025;8(3):e250001. https:\/\/doi.org\/10.1001\/jamanetworkopen.2025.0001.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"702_CR8","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.37419\/LR.V12.I4.6","volume":"12","author":"SA Tovino","year":"2025","unstructured":"Tovino SA. Dialing in or Dialing out? The Relationship between State Telemedicine Law and Access to Buprenorphine. Tex AM Law Rev 2024. 2025;12(4):1595\u2013682. https:\/\/doi.org\/10.37419\/LR.V12.I4.6.","journal-title":"Tex AM Law Rev 2024"},{"issue":"1","key":"702_CR9","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s12954-023-00756-3","volume":"20","author":"S Brothers","year":"2023","unstructured":"Brothers S, Palayew A, Simon C, Coulter A, Strichartz K, Voyles N, et al. Patient experiences of methadone treatment changes during the first wave of COVID-19: a national community-driven survey. Harm Reduct J. 2023;20(1):31. https:\/\/doi.org\/10.1186\/s12954-023-00756-3.","journal-title":"Harm Reduct J"},{"issue":"3","key":"702_CR10","doi-asserted-by":"publisher","first-page":"e223821","DOI":"10.1001\/jamanetworkopen.2022.3821","volume":"5","author":"PM Mauro","year":"2022","unstructured":"Mauro PM, Gutkind S, Annunziato EM, Samples H. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019. JAMA Netw Open. 2022;5(3):e223821. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.3821.","journal-title":"JAMA Netw Open"},{"key":"702_CR11","doi-asserted-by":"publisher","unstructured":"Dowell D. Treatment for opioid use disorder: population estimates\u2014United States, 2022. MMWR Morb Mortal Wkly Rep. 2024;73. https:\/\/doi.org\/10.15585\/mmwr.mm7325a1.","DOI":"10.15585\/mmwr.mm7325a1"},{"issue":"1","key":"702_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/ADM.0000000000000739","volume":"15","author":"B Chan","year":"2021","unstructured":"Chan B, Gean E, Arkhipova-Jenkins I, Gilbert J, Hilgart J, Fiordalisi C, et al. Retention Strategies for Medications for Opioid Use Disorder in Adults: A Rapid Evidence Review. J Addict Med. 2021;15(1):74. https:\/\/doi.org\/10.1097\/ADM.0000000000000739.","journal-title":"J Addict Med"},{"key":"702_CR13","doi-asserted-by":"publisher","first-page":"209310","DOI":"10.1016\/j.josat.2024.209310","volume":"160","author":"VI Villamil","year":"2024","unstructured":"Villamil VI, Underwood N, Cremer LJ, Rooks-Peck CR, Jiang X, Guy GP. Barriers to retention in medications for opioid use disorder treatment in real-world practice. J Subst Use Addict Treat. 2024;160:209310. https:\/\/doi.org\/10.1016\/j.josat.2024.209310.","journal-title":"J Subst Use Addict Treat"},{"issue":"1","key":"702_CR14","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1097\/ADM.0000000000000739","volume":"15","author":"B Chan","year":"2021","unstructured":"Chan B, Gean E, Arkhipova-Jenkins I, Gilbert J, Hilgart J, Fiordalisi C, et al. Retention strategies for medications for opioid use disorder in adults: a rapid evidence review. J Addict Med. 2021;15(1):74\u201384. https:\/\/doi.org\/10.1097\/ADM.0000000000000739. PubMed PMID: 32956162; PubMed Central PMCID: PMC7864607.","journal-title":"J Addict Med"},{"key":"702_CR15","unstructured":"Atherton E, Schweninger E, Edmunds M. Transportation: a community driver of health. Washington (DC): American Public Health Association, AcademyHealth, and Kaiser Permanente; 2021. Available from: https:\/\/www.apha.org\/news-and-media\/news-releases\/apha-news-releases\/2021\/community-drivers-of-health-policy-papers"},{"issue":"5","key":"702_CR16","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1007\/s10900-013-9681-1","volume":"38","author":"ST Syed","year":"2013","unstructured":"Syed ST, Gerber BS, Sharp LK. Traveling Towards Disease: Transportation Barriers to Health Care Access. J Community Health. 2013;38(5):976. https:\/\/doi.org\/10.1007\/s10900-013-9681-1. PubMed PMID: 23543372.","journal-title":"J Community Health"},{"issue":"6","key":"702_CR17","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2105\/AJPH.2020.305579","volume":"110","author":"MK Wolfe","year":"2020","unstructured":"Wolfe MK, McDonald NC, Holmes GM. Transportation Barriers to Health Care in the United States: Findings From the National Health Interview Survey, 1997\u20132017. Am J Public Health. 2020;110(6):815\u201322. https:\/\/doi.org\/10.2105\/AJPH.2020.305579. PubMed PMID: 32298170; PubMed Central PMCID: PMC7204444.","journal-title":"Am J Public Health"},{"key":"702_CR18","unstructured":"RWJF [Internet]. [cited 2025 Feb 4]. More than one in five adults forgo healthcare because of transportation barriers. Available from: https:\/\/www.rwjf.org\/content\/rwjf-web\/us\/en\/insights\/our-research\/2023\/04\/more-than-one-in-five-adults-with-limited-public-transit-access-forgo-healthcare-because-of-transportation-barriers.html."},{"issue":"5","key":"702_CR19","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1016\/j.healthplace.2010.06.012","volume":"16","author":"D Dai","year":"2010","unstructured":"Dai D. Black residential segregation, disparities in spatial access to health care facilities, and late-stage breast cancer diagnosis in metropolitan Detroit. Health Place. 2010;16(5):1038\u201352. https:\/\/doi.org\/10.1016\/j.healthplace.2010.06.012.","journal-title":"Health Place"},{"issue":"6","key":"702_CR20","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.puhe.2015.04.001","volume":"129","author":"N Douthit","year":"2015","unstructured":"Douthit N, Kiv S, Dwolatzky T, Biswas S. Exposing some important barriers to health care access in the rural USA. Public Health. 2015;129(6):611\u201320. https:\/\/doi.org\/10.1016\/j.puhe.2015.04.001.","journal-title":"Public Health"},{"issue":"1","key":"702_CR21","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1080\/00330120701724087","volume":"60","author":"F Wang","year":"2008","unstructured":"Wang F, McLafferty S, Escamilla V, Luo L. Late-Stage Breast Cancer Diagnosis and Health Care Access in Illinois\u2217. Prof Geogr. 2008;60(1):54\u201369. https:\/\/doi.org\/10.1080\/00330120701724087.","journal-title":"Prof Geogr"},{"key":"702_CR22","unstructured":"CCM KA BSN RN, BC RN. How to address SDOH transportation barriers [Internet]. [cited 2025 Feb 4]. Available from: https:\/\/www.thoroughcare.net\/blog\/address-sdoh-transportation-barriers."},{"key":"702_CR23","unstructured":"Social Determinants of Health Literature Summaries - Healthy People 2030 | odphp.health.gov [Internet]. [cited 2025 Feb 4]. Available from: https:\/\/odphp.health.gov\/healthypeople\/priority-areas\/social-determinants-health\/literature-summaries."},{"issue":"2","key":"702_CR24","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1007\/s10900-018-0572-3","volume":"44","author":"LE Starbird","year":"2019","unstructured":"Starbird LE, DiMaina C, Sun CA, Han HR. A systematic review of interventions to minimize transportation barriers among people with chronic diseases. J Community Health. 2019;44(2):400. https:\/\/doi.org\/10.1007\/s10900-018-0572-3. PubMed PMID: 30206755.","journal-title":"J Community Health"},{"issue":"2","key":"702_CR25","first-page":"178","volume":"18","author":"SM Locatelli","year":"2017","unstructured":"Locatelli SM, Sharp LK, Syed ST, Bhansari S, Gerber BS. Measuring Health-related Transportation Barriers in Urban Settings. J Appl Meas. 2017;18(2):178. PubMed PMID: 28961153.","journal-title":"J Appl Meas"},{"issue":"8","key":"702_CR26","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1377\/hlthaff.2023.01332","volume":"43","author":"J Tsai","year":"2024","unstructured":"Tsai J, Szymkowiak D, Beydoun H, Dasilva L, Transportation As A, Determinant Of Health. Evaluating The Veterans Affairs Rideshare Program For Homeless Patients. Health Aff (Millwood). 2024;43(8):1090\u20139. https:\/\/doi.org\/10.1377\/hlthaff.2023.01332.","journal-title":"Health Aff (Millwood)"},{"key":"702_CR27","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13011-025-00644-y","volume":"20","author":"HK Knudsen","year":"2025","unstructured":"Knudsen HK, Andrews-Higgins S, Back-Haddix S, Lofwall MR, Fanucchi L, Walsh SL. Barriers and facilitators to scaling up medications for opioid use disorder in Kentucky: qualitative perspectives of treatment organization staff. Subst Abuse Treat Prev Policy. 2025;20:15. https:\/\/doi.org\/10.1186\/s13011-025-00644-y. PubMed PMID: 40176107; PubMed Central PMCID: PMC11963284.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"702_CR28","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. https:\/\/doi.org\/10.1136\/bmj.j1550. PubMed PMID: 28446428; PubMed Central PMCID: PMC5421454.","journal-title":"BMJ"},{"key":"702_CR29","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.tranpol.2024.08.001","volume":"156","author":"NS Ngo","year":"2024","unstructured":"Ngo NS, Anand K. Affordable transportation access to treatment for opioid use disorder. Transp Policy. 2024;156:152\u201363. https:\/\/doi.org\/10.1016\/j.tranpol.2024.08.001.","journal-title":"Transp Policy"},{"key":"702_CR30","doi-asserted-by":"publisher","first-page":"108093","DOI":"10.1016\/j.jsat.2020.108093","volume":"117","author":"C Drake","year":"2020","unstructured":"Drake C, Donohue J, Nagy D, Mair C, Kraemer K, Wallace D. Geographic access to buprenorphine prescribers for patients who use public transit. J Subst Abuse Treat. 2020;117:108093. https:\/\/doi.org\/10.1016\/j.jsat.2020.108093. PubMed PMID: 32811632; PubMed Central PMCID: PMC7446662.","journal-title":"J Subst Abuse Treat"},{"key":"702_CR31","doi-asserted-by":"publisher","first-page":"108727","DOI":"10.1016\/j.drugalcdep.2021.108727","volume":"224","author":"S Amiri","year":"2021","unstructured":"Amiri S, Hirchak K, McDonell MG, Denney JT, Buchwald D, Amram O. Access to medication-assisted treatment in the United States: Comparison of travel time to opioid treatment programs and office-based buprenorphine treatment. Drug Alcohol Depend. 2021;224:108727. https:\/\/doi.org\/10.1016\/j.drugalcdep.2021.108727.","journal-title":"Drug Alcohol Depend"},{"key":"702_CR32","doi-asserted-by":"publisher","first-page":"108335","DOI":"10.1016\/j.drugalcdep.2020.108335","volume":"217","author":"HEALing Communities Study Consortium","year":"2020","unstructured":"HEALing Communities Study Consortium. The HEALing (Helping to End Addiction Long-term SM) Communities Study: Protocol for a cluster randomized trial at the community level to reduce opioid overdose deaths through implementation of an integrated set of evidence-based practices. Drug Alcohol Depend. 2020;217:108335. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108335. PubMed PMID: 33248391; PubMed Central PMCID: PMC7568493.","journal-title":"Drug Alcohol Depend"},{"key":"702_CR33","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-5440415\/v1","author":"HK Knudsen","year":"2024","unstructured":"Knudsen HK, Andrews-Higgins S, Back-Haddix S, Lofwall MR, Fanucchi L, Walsh SL. Scaling up medications for opioid use disorder in Kentucky: Qualitative perspectives of treatment organizations. Res Sq. 2024. https:\/\/doi.org\/10.21203\/rs.3.rs-5440415\/v1. PubMed PMID: 39711557; PubMed Central PMCID: PMC11661295. rs.3.rs-5440415.","journal-title":"Res Sq"},{"key":"702_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001459","author":"A Fallin-Bennett","year":"2024","unstructured":"Fallin-Bennett A, Moffitt T, Walsh SL, Lofwall M, Miles J, Underwood C, et al. We Drove to the Moon: Ensuring Methadone Access in Rural Kentucky through Peer Transportation. J Addict Med. 2024. https:\/\/doi.org\/10.1097\/ADM.0000000000001459.","journal-title":"J Addict Med"},{"key":"702_CR35","doi-asserted-by":"publisher","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap) \u2014a metadata-driven methodology and workflow process for providing translational research informatics support.J Biomed Inform. 2009;42(2):377\u201381. https:\/\/doi.org\/10.1016\/j.jbi.2008.08.010. PubMed PMID: 18929686; PubMed Central PMCID: PMC2700030.","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"702_CR36","doi-asserted-by":"publisher","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","volume":"95","author":"PA Harris","year":"2019","unstructured":"Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O\u2019Neal L, et al. The REDCap Consortium: Building an International Community of Software Platform Partners. J Biomed Inf. 2019;95:103208. https:\/\/doi.org\/10.1016\/j.jbi.2019.103208. PubMed PMID: 31078660; PubMed Central PMCID: PMC7254481.","journal-title":"J Biomed Inf"},{"key":"702_CR37","unstructured":"Reach of community-selected strategies to reduce opioid-related overdose deaths in the HEALing Communities Study [Internet]. [cited 2026 May 20]. Available from: https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10826084.2025.2549496#d1e401."},{"key":"702_CR38","doi-asserted-by":"publisher","first-page":"108330","DOI":"10.1016\/j.drugalcdep.2020.108330","volume":"217","author":"HK Knudsen","year":"2020","unstructured":"Knudsen HK, Drainoni ML, Gilbert L, Huerta TR, Oser CB, Aldrich AM, et al. Model and approach for assessing implementation context and fidelity in the HEALing Communities Study. Drug Alcohol Depend. 2020;217:108330. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108330. PubMed PMID: 33086156; PubMed Central PMCID: PMC7531282.","journal-title":"Drug Alcohol Depend"},{"key":"702_CR39","doi-asserted-by":"publisher","unstructured":"Glasgow RE, Harden SM, Gaglio B, Rabin B, Smith ML, Porter GC, et al. RE-AIM planning and evaluation framework: adapting to new science and practice with a 20-year review. Front Public Health. 2019;7. https:\/\/doi.org\/10.3389\/fpubh.2019.00064.","DOI":"10.3389\/fpubh.2019.00064"},{"key":"702_CR40","unstructured":"RADOR-KY: Dashboard [Internet]. [cited 2026 May 7]. Available from: https:\/\/rador-ky.uky.edu\/."},{"key":"702_CR41","unstructured":"CDC. National Center for Health Statistics [Internet]; 2025 [cited 2026 May 20]. NCHS urban-rural classification scheme for counties. Available from: https:\/\/www.cdc.gov\/nchs\/data-analysis-tools\/urban-rural.html."},{"issue":"166","key":"702_CR42","first-page":"1","volume":"2014","author":"DD Ingram","year":"2013","unstructured":"Ingram DD, Franco SJ. NCHS Urban-Rural Classification Scheme for Counties. Vital Health Stat 2. 2013;2014(166):1\u201373. PubMed PMID: 24776070.","journal-title":"Vital Health Stat 2"},{"key":"702_CR43","unstructured":"Kentucky County Population Trends in 2023 [Internet]. [cited 2026 Jun 3]. Available from: https:\/\/kaco.org\/articles\/kentucky-county-population-trends-in-2023\/."},{"key":"702_CR44","unstructured":"Kentucky General Assembly. Kentucky Legislative Research Commission [Internet]; 2024 [cited 2024 Dec 8]. Title 908 Chap. 2 Regulation 220 \u2022 Kentucky Administrative Regulations \u2022 Legislative Research Commission. Available from: https:\/\/apps.legislature.ky.gov\/law\/kar\/titles\/908\/002\/220\/."},{"key":"702_CR45","unstructured":"National Academies of Sciences, Engineering, and Medicine; Division on Earth and Life Studies; Health and Medicine Division; Board on Health Sciences Policy; Committee on Medication-Assisted Treatment for Opioid Use Disorder. Barriers to broader use of medications to treat opioid use disorder. In: Medications for opioid use disorder save lives [Internet]. Mancher M, Leshner AI, editors. Washington (DC): National Academies Press (US); 2019 [cited 2025 Jul 3]. Chapter 5. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK541389\/."},{"key":"702_CR46","unstructured":"Telehealth and medications for opioid use disorder [Internet]. [cited 2025 Feb 4]. Available from: https:\/\/telehealth.hhs.gov\/providers\/best-practice-guides\/telehealth-substance-use-disorder\/telehealth-and-medications-opioid."},{"issue":"1","key":"702_CR47","doi-asserted-by":"publisher","first-page":"e12854","DOI":"10.1111\/jrh.12854","volume":"41","author":"G Pro","year":"2025","unstructured":"Pro G, Cantor J, Willis D, Gu M, Fairman B, Baloh J, et al. A multilevel analysis of changing telehealth availability in opioid use disorder treatment settings: Conditional effects of rurality, the number and types of medication for opioid use disorder available, and time, US, 2016\u20132023. J Rural Health Off J Am Rural Health Assoc Natl Rural Health Care Assoc. 2025;41(1):e12854. https:\/\/doi.org\/10.1111\/jrh.12854. PubMed PMID: 38867390.","journal-title":"J Rural Health Off J Am Rural Health Assoc Natl Rural Health Care Assoc"},{"key":"702_CR48","unstructured":"National Quality Forum. Quality ID #468: Continuity of pharmacotherapy for opioid use disorder (OUD) - National Quality Strategy Domain: effective clinical care; meaningful measure area: prevention and treatment of opioid and substance use disorders. [Internet]; 2022. Available from: https:\/\/qpp.cms.gov\/docs\/QPP_quality_measure_specifications\/CQM-Measures\/2019_Measure_468_MIPSCQM.pdf."}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-026-00702-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00702-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00702-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T23:02:09Z","timestamp":1792364529000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-026-00702-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["702"],"URL":"https:\/\/doi.org\/10.1186\/s13722-026-00702-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-7999770\/v1","asserted-by":"object"}]},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"31 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study protocol (Pro00038088) was approved by Advarra Inc., the HEALing Communities Study single Institutional Review Board. For this type of study, formal consent was not required as we received a waiver of consent. All partner organizations agreed to provide anonymous data on transportation service support distribution as part of the contractual agreement. Advarra is organized and operates in compliance with the U.S. federal regulations and the ethical principles underlying the involvement of human subjects in research (including The Belmont Report, Nuremberg Code, Declaration of Helsinki). IRB Accreditation And Compliance | Advarra.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"76"}}